SCIB1
SCIB1
SCIB1 (pronounced "skib-one") is a DNA-based cancer vaccine developed by Scancell Holdings, a British biopharmaceutical company. It is designed to stimulate the immune system to fight melanoma, a type of skin cancer.
Etymology
The term "SCIB1" is an acronym derived from the name of the company that developed it, Scancell, and the designation IB1 is a code used by the company to identify this particular vaccine.
Mechanism of Action
SCIB1 works by stimulating the body's immune system to produce T cells that recognize and kill melanoma cells. It does this by encoding a protein called TRP-2, which is often found in melanoma cells. When the vaccine is injected into the body, it instructs the immune system to target cells expressing TRP-2, thereby helping to eliminate the cancer.
Clinical Trials
As of 2021, SCIB1 is in Phase II clinical trials. The trials aim to evaluate the safety and efficacy of the vaccine in patients with stage III/IV melanoma. Preliminary results have shown promise, with some patients experiencing a reduction in tumor size and improved survival rates.
Related Terms
- Scancell Holdings: The British biopharmaceutical company that developed SCIB1.
- Melanoma: A type of skin cancer that SCIB1 is designed to treat.
- TRP-2: A protein often found in melanoma cells, which SCIB1 instructs the immune system to target.
- Clinical trial: A research study conducted to evaluate the safety and efficacy of new drugs or treatments. SCIB1 is currently in Phase II clinical trials.
External links
- Medical encyclopedia article on SCIB1
- Wikipedia's article - SCIB1
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski